These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

854 related articles for article (PubMed ID: 33306195)

  • 41. Programmed cell death protein 1 activation preferentially inhibits CD28.CAR-T cells.
    Zolov SN; Rietberg SP; Bonifant CL
    Cytotherapy; 2018 Oct; 20(10):1259-1266. PubMed ID: 30309710
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Increased Peripheral NKG2A-NKG2D+CD3-CD16+CD56dim NK Cell Subset Was Positively Correlated with Antiphospholipid Antibodies in Patients of Obstetric Antiphospholipid Syndrome.
    Zhang Y; Zhao Y; Si W; Yang B; Lin M; Zheng J; Cui L
    Immunol Invest; 2022 Feb; 51(2):425-437. PubMed ID: 33103514
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cytotoxicity of CD56(bright) NK cells towards autologous activated CD4+ T cells is mediated through NKG2D, LFA-1 and TRAIL and dampened via CD94/NKG2A.
    Nielsen N; Ødum N; Ursø B; Lanier LL; Spee P
    PLoS One; 2012; 7(2):e31959. PubMed ID: 22384114
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Assay of T- and NK-cell subsets and the expression of NKG2A and NKG2D in patients with new-onset systemic lupus erythematosus.
    Li WX; Pan HF; Hu JL; Wang CZ; Zhang N; Li J; Li XP; Xu JH; Ye DQ
    Clin Rheumatol; 2010 Mar; 29(3):315-23. PubMed ID: 20012119
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A New Hope for CD56
    Forconi CS; Oduor CI; Oluoch PO; Ong'echa JM; Münz C; Bailey JA; Moormann AM
    Front Cell Infect Microbiol; 2020; 10():162. PubMed ID: 32373555
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical significance of signal regulatory protein alpha and T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif domain expression in undifferentiated pleomorphic sarcoma.
    Ishihara S; Iwasaki T; Kohashi K; Kawaguchi K; Toda Y; Fujiwara T; Setsu N; Endo M; Matsumoto Y; Nakashima Y; Oda Y
    J Cancer Res Clin Oncol; 2023 Jun; 149(6):2425-2436. PubMed ID: 35737088
    [TBL] [Abstract][Full Text] [Related]  

  • 47. DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer.
    Sasidharan Nair V; El Salhat H; Taha RZ; John A; Ali BR; Elkord E
    Clin Epigenetics; 2018; 10():78. PubMed ID: 29983831
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tim-3 and PD-1 blocking cannot restore the functional properties of natural killer cells in early clinical stages of chronic lymphocytic leukemia: An
    Astaneh M; Rezazadeh H; Hossein-Nataj H; Shekarriz R; Zaboli E; Shabani M; Asgarian-Omran H
    J Cancer Res Ther; 2022; 18(3):704-711. PubMed ID: 35900543
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Natural killer cell subsets and receptor expression in peripheral blood mononuclear cells of a healthy Korean population: Reference range, influence of age and sex, and correlation between NK cell receptors and cytotoxicity.
    Phan MT; Chun S; Kim SH; Ali AK; Lee SH; Kim S; Kim SH; Cho D
    Hum Immunol; 2017 Feb; 78(2):103-112. PubMed ID: 27884732
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Innate Lymphoid Cells: Expression of PD-1 and Other Checkpoints in Normal and Pathological Conditions.
    Mariotti FR; Quatrini L; Munari E; Vacca P; Moretta L
    Front Immunol; 2019; 10():910. PubMed ID: 31105707
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Strong capacity of differentiated PD-L1 CAR-modified UCB-CD34
    Ghaedrahmati F; Akbari V; Seyedhosseini-Ghaheh H; Esmaeil N
    Stem Cell Res Ther; 2024 Aug; 15(1):257. PubMed ID: 39135206
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Increased coexpression of PD-L1 and TIM3/TIGIT is associated with poor overall survival of patients with esophageal squamous cell carcinoma.
    Wang P; Chen Y; Long Q; Li Q; Tian J; Liu T; Wu Y; Ding Z
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34625514
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The importance of the PD-1/PD-L1 pathway at the maternal-fetal interface.
    Meggyes M; Miko E; Szigeti B; Farkas N; Szereday L
    BMC Pregnancy Childbirth; 2019 Feb; 19(1):74. PubMed ID: 30782114
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dysfunction of natural killer cells mediated by PD-1 and Tim-3 pathway in anaplastic thyroid cancer.
    Yin M; Di G; Bian M
    Int Immunopharmacol; 2018 Nov; 64():333-339. PubMed ID: 30243069
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adipocytes affect castration-resistant prostate cancer cells to develop the resistance to cytotoxic action of NK cells with alterations of PD-L1/NKG2D ligand levels in tumor cells.
    Xu L; Shen M; Chen X; Zhu R; Yang DR; Tsai Y; Keng PC; Chen Y; Lee SO
    Prostate; 2018 Apr; 78(5):353-364. PubMed ID: 29330929
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Identification and functional analysis of ligands for natural killer cell activating receptors in colon carcinoma.
    Zhang Z; Su T; He L; Wang H; Ji G; Liu X; Zhang Y; Dong G
    Tohoku J Exp Med; 2012 Jan; 226(1):59-68. PubMed ID: 22189020
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer.
    Wan C; Keany MP; Dong H; Al-Alem LF; Pandya UM; Lazo S; Boehnke K; Lynch KN; Xu R; Zarrella DT; Gu S; Cejas P; Lim K; Long HW; Elias KM; Horowitz NS; Feltmate CM; Muto MG; Worley MJ; Berkowitz RS; Matulonis UA; Nucci MR; Crum CP; Rueda BR; Brown M; Liu XS; Hill SJ
    Cancer Res; 2021 Jan; 81(1):158-173. PubMed ID: 33158814
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Indirect Impact of PD-1/PD-L1 Blockade on a Murine Model of NK Cell Exhaustion.
    Alvarez M; Simonetta F; Baker J; Morrison AR; Wenokur AS; Pierini A; Berraondo P; Negrin RS
    Front Immunol; 2020; 11():7. PubMed ID: 32117218
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Differential alteration of CD56(bright) and CD56 (dim) natural killer cells in frequency, phenotype, and cytokine response in chronic hepatitis C virus infection.
    Miyagi T; Shimizu S; Tatsumi T; Nishio K; Hiramatsu N; Kanto T; Hayashi N; Takehara T
    J Gastroenterol; 2011 Aug; 46(8):1020-30. PubMed ID: 21559771
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impaired natural killer cell subset phenotypes in human obesity.
    Bähr I; Jahn J; Zipprich A; Pahlow I; Spielmann J; Kielstein H
    Immunol Res; 2018 Apr; 66(2):234-244. PubMed ID: 29560551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.